MEIRAGTX HOLDINGS PLC (MGTX)
Health Care · Gene therapy and genetic medicines · NASDAQ
A vertically integrated clinical-stage genetic medicines company developing locally-delivered gene therapies for ophthalmology, Parkinson's disease, and xerostomia, backed by proprietary viral vector manufacturing and riboswitch gene regulation technology.
What MEIRAGTX HOLDINGS PLC does
MeiraGTx is a clinical-stage genetic medicines company focused on developing therapies using localized delivery of genetic medicines to treat inherited and common diseases with high unmet need. The company has built comprehensive end-to-end manufacturing capabilities, including two GMP-licensed viral vector production facilities in London and Shannon, and a proprietary manufacturing platform optimized over 9+ years. Beyond gene therapy, the company has developed a transformative riboswitch gene regulation platform enabling precise, oral dose-responsive control of gene expression for metabolic peptides, cell therapy, and pain management.
Themes: Gene therapy / genetic medicines, Viral vectors and capsid engineering, Ophthalmology / inherited retinal disease, Parkinson's disease, Riboswitch technology / synthetic gene regulation, GLP-1 delivery systems, CAR-T cell therapy, Biomanufacturing / GMP manufacturing, Metabolic peptide therapeutics, Pain management / neurology
Fundamentals
- Price$14.34 as of 2026-08-21 close
- Market cap$1.4B as of 2026-08-21
- 1-year return+82.7% 2025-08-21 close $7.85 → 2026-08-21 close $14.34
- P/En/a negative earnings
- Net margin-151.1% as of 2026-08-24
- Gross margin+95.4% as of 2026-08-24
- ROE-315.6% as of 2026-08-24
- Debt / equity24.92 as of 2026-08-24
- Revenue growth (YoY)+131.1% as of 2026-08-24
- Revenue CAGR (3y)+141.0% SEC XBRL
- Beta1.33 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How MGTX compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How MEIRAGTX HOLDINGS PLC looks technically
MEIRAGTX HOLDINGS PLC (MGTX) is trading 52.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 84 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 52.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +52.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.47 | $12.47 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $9.42 | $9.42 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 11.28. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 84 trading days ago — a "golden cross", a bullish long-term signal | 84 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with buyers in control | 33.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30) | 64.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($11.91 to $15.05) — its "stochastic" reading is 77 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 77.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $15.35 | $15.35 |
|---|---|---|
| From the 52-week high | it is 6.6% below its 52-week high (its highest price of the past year) | -6.6% |
| Above the 52-week low | it is 116.6% above its 52-week low (its lowest price of the past year) | +116.6% |
| Below the 52-week high | it is 6.6% below its highest point of the past year | 6.6% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $30.23 (set on 2019-07-09) | $30.23 |
| Given back of the 52-week move | over the past year its closes ranged ($6.99 to $14.97), and it has given back only a small part of its rise from last year’s low — 8% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.78 to $10.04. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 7.9% |
| From the all-time high | it is 52.6% below its all-time high | -52.6% |
| Nearest price level | it is trading 33.8% above a support level at $9.50 — a price it turned at twice since 2025-10-28, most recently on 2025-12-12. Since 2024-08-21 it has 17 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -33.8% |
| All-time low | its lowest closing price on record is $3.49 (set on 2023-10-25) | $3.49 |
| Above the all-time low | it is 310.9% above its all-time low | +310.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 71% of it) | 71st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7209 between its high and its low — about 5.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7209 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $11.04 and $14.84 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $11.04 – $12.94 – $14.84 |
| Typical daily range (% of price) | its price moves about 5.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.0% |
| Stretch from the 200-day average | it is trading 6.8 daily ranges above its 200-day average price (52.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.04× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.5% since the prior reading | +0.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 2.9% above the previous close 2 sessions ago and has not traded back through the level it left behind at 13.89 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.9% |
| Gap filled | a 9.5% gap up opened on 2026-08-13 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 6 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -4.21% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 12.2 percentage points (the stock gained 14.5% while the market gained 2.3%) | +12.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 48.0 percentage points (the stock gained 51.1% while the market gained 3.1%) | +48.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 81.4 percentage points (the stock gained 92.5% while the market gained 11.1%) | +81.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 62.2 percentage points (the stock gained 82.7% while the market gained 20.5%) | +62.2% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.1% of the share price. | +11.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 39% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $10.32 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +38.9% |
|---|
Price levels it has turned at before
MGTX last closed at $14.34 on 2026-08-21. Since 2024-08-21 it has turned at 17 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $9.50 | Support | 33.8% below the last close | turned there twice · 2025-10-28 to 2025-12-12 |
| $8.95 | Support | 37.6% below the last close | turned there four times · 2025-07-15 to 2026-06-11 |
| $8.72 | Support | 39.2% below the last close | turned there five times · 2025-03-14 to 2026-04-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $11.28.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $17.73 and $21.72 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $11.28.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market · Stretched far above its 200-day average (6+ daily ranges) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.29 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$29.43 range $19.00 – $50.00; median $27.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MGTX
- Consensus EPS estimate-$0.455 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical stage company with no approved products and unprofitable operations (net margin -151%); success depends entirely on regulatory approval and clinical efficacy of late-stage pipeline candidates","Dependence on strategic partnerships (Janssen, Eli Lilly, Hologen) for funding and commercialization; changes in partner strategy or funding could materially impact development timelines","Manufacturing complexity and regulatory risk; GMP facility compliance failures or supply disruptions could delay or prevent product launches"]
What changed in the latest 10-Q
AI-assisted comparison of MGTX's 10-Q filed 2026-05-14 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-14) adds: reference to Form 10-K for year ended December 31, 2025 (versus 2024 in older filing)
- Newer filing adds: description of 'four late-stage clinical programs' with explicit mention of programs 'in the eye, Parkinson's disease and radiation-induced xerostomia'
- Newer filing adds: specific reference to 'GMP Quality Control facility with clinical and commercial licensure'
- Newer filing adds: detailed description of 'proprietary manufacturing platform process over 9 years based on more than 20 different viral vectors'
- Newer filing adds: expanded riboswitch platform focus including 'CAR-T for liquid and solid tumors and autoimmune diseases, and additionally, PNS targets addressing long-term intractable pain'
- Newer filing adds: reference to Framework Agreements dated March 9, 2025 with Hologen Limited and affiliates
- Newer filing adds: reference to Strategic Collaboration and License Agreement dated November 7, 2025 with Eli Lilly and Company (Lilly Collaboration Agreement)
- Newer filing adds: updated cumulative gross proceeds through March 31, 2026 of approximately $651.3 million from equity sales, and total of $435.0 million from collaboration, license, framework and asset purchase agreements
- Newer filing adds: cash position of $73.8 million as of March 31, 2026 and $3.3 million receivable from Janssen for PPQ and transition services
- Newer filing adds: net losses for three-month period ended March 31, 2026 of $46.3 million (versus March 31, 2025 of $40.0 million)
- Newer filing adds: accumulated deficit of $862.5 million as of March 31, 2026
- Newer filing adds: operating expenses of $41.1 million for three-month period ended March 31, 2026 (versus $43.5 million for comparable 2025 period)
- Newer filing adds: expectation that increases relating to AAV-GAD funding will be offset by Hologen strategic collaboration funding
- Newer filing adds: reference to costs for AAV-AIPL1 that 'can be offset by the funding in connection with the Lilly Collaboration Agreement'
- Removed:
- Older filing (2025-11-13) describes pipeline as 'late-stage clinical programs, including Parkinson's disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy' - newer filing removes specific mention of 'AIPL1-associated retinal dystrophy' from this introductory sentence
- Older filing references 'Johnson & Johnson Innovative Medicine (formerly known as Janssen Pharmaceuticals, Inc.)' - newer filing uses simplified reference to 'Janssen Pharmaceuticals, Inc.' or 'Janssen'
- Older filing references 'Collaboration Agreement' and 'Asset Purchase Agreement' - newer filing adds specific formal names 'Janssen Collaboration Agreement' and 'Original Asset Purchase Agreement'
- Older filing describes sale of UCLB RPGR License Agreement to Johnson & Johnson Innovative Medicine - newer filing simplifies language to direct asset sale description
- Older filing references cumulative gross proceeds through September 30, 2025 of $632.2 million from equity and $130.0 million and $125.0 million from specific agreements - these figures are replaced with updated March 31, 2026 figures
- Older filing reports cash position of $17.1 million as of September 30, 2025 - replaced with $73.8 million as of March 31, 2026
- Older filing reports accumulated deficit of $831.3 million as of September 30, 2025 - replaced with $862.5 million as of March 31, 2026
- Older filing references net losses for nine-month periods - newer filing only reports three-month period data
- Older filing mentions costs for 'xerostomia associated with Sjogren's syndrome' - newer filing removes Sjogren's syndrome reference
- Older filing references 'costs associated with the delivery of services under the Asset Purchase Agreement and related agreements' - newer filing removes this language
- Reworded:
- Older: 'late-stage clinical programs' versus Newer: 'four late-stage clinical programs' - adds quantification of programs
- Older: 'targeted local delivery' versus Newer: 'local delivery of small doses' - minor wording shift
- Older: 'Our core capabilities in viral vector and capsid optimization' versus Newer: 'We use our innovative technology in optimization of capsids, promoters, and novel translational control elements' - expanded technical description
- Older: 'bespoke synthetic riboswitch technology invented in-house' versus Newer: 'novel technology for in vivo delivery' and 'transformative riboswitch gene regulation technology' - reframing of technology description
- Older: 'allows for the precise, dose-responsive control of any transgene under the control of oral small molecules' versus Newer: 'allows precise, dose-responsive control of gene expression by oral small molecules' - simplified phrasing
- Older: 'in vivo delivery of biologic therapeutics such as the metabolic peptides' versus Newer: 'regulated in vivo delivery of metabolic peptides' - adds 'regulated' descriptor
- Older: 'cell therapy for oncology and autoimmune diseases, and long-term intractable pain' versus Newer: 'cell therapy, CAR-T for liquid and solid tumors and autoimmune diseases, and additionally, PNS targets addressing long-term intractable pain' - more specific terminology
- Older: 'We have developed unique comprehensive technology capabilities' versus Newer: 'We have developed the technology' - simplification
- Older: 'Company' versus Newer: 'company' - capitalization change in one instance
- Older: references 'upfront and milestone payments' versus Newer: specifies 'upfront and milestone payments in connection with' for clarity
- Older: 'process performance qualification' abbreviated as 'PPQ' - Newer maintains same abbreviation but both texts use it
- Notes:
- Older filing text appears truncated at end of visible section; newer filing also appears truncated mid-sentence
- Comparison limited to provided excerpts; full MD&A sections may contain additional changes not visible in truncated text
- Financial figures represent different reporting periods (March 31, 2026 versus September 30, 2025), making period-over-period comparisons not directly comparable
- Collaboration agreement entity naming conventions changed between filings (Janssen vs. Johnson & Johnson Innovative Medicine terminology)
Risk Factors
- Added:
- Newer filing (2026-05-14) adds specific mention of costs related to long-term follow up study for Phase 3 LUMEOS clinical trial of bota-vec for XLRP treatment
- Newer filing (2026-05-14) adds explicit statement that Hologen funding is 'part of the strategic collaboration we entered into with them' (versus older filing's 'anticipated closing')
- Newer filing (2026-05-14) specifies 'increasing research, preclinical and clinical activities for our riboswitch platform' separately from AAV-GAD activities
- Removed:
- Older filing (2025-11-13) contained a separate risk factor section titled 'There is no guarantee that we will receive in a timely fashion or at all the additional milestone payments contemplated under the Asset Purchase Agreement or the revenues associated with our manufacture of the commercial supply of the RPGR Product under the Supply Agreement' with details about the December 20, 2023 Johnson & Johnson transaction—this section is not present in newer filing (2026-05-14)
- Reworded:
- Net loss figures changed from 'nine months ended September 30, 2025, and 2024' ($129.3 million and $108.4 million) in older filing to 'three months ended March 31, 2026, and 2025' ($46.3 million and $40.0 million) in newer filing
- Accumulated deficit changed from '$831.3 million' as of September 30, 2025 in older filing to '$862.5 million' as of March 31, 2026 in newer filing
- Hologen funding language changed from 'although certain of these increases are expected to be offset by the funding provided by Hologen after the anticipated closing of the strategic collaboration we entered into with them' to 'although certain of these increases are expected to be offset by the funding provided by Hologen as part of the strategic collaboration we entered into with them'
- Older filing references 'EMA,' (with comma after parenthesis) while newer filing references 'EMA' (without comma)
- Notes:
- The newer filing appears truncated at the end ('Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business s'), suggesting the full text may not have been provided for comparison
- The older filing text also appears truncated at the end regarding the Johnson & Johnson Asset Purchase Agreement details, limiting full assessment of removals
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 3 sells ($1M) — 2 selling insiders
- Last 180 days0 buys · 5 sells ($2M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-21. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MGTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
MGTX had 3,897,920 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
MGTX had 4.06% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.27 days to cover at the same settlement.
- Reported short interest (shares) 3,897,920
- Short interest (% of shares outstanding) 4.06%
- Prior settlement (shares) 4,215,627
- Reported change -7.54%
- Days to cover (reported) 8.27
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Spark Therapeutics (ONCE)
- Audentes Therapeutics (now part of Astellas)
- Regenxbio (RGNX)
- uniQure (QURE)
- Sangamo Therapeutics (SGMO)
- Gensight Biologics (part of Novartis)
- Eli Lilly (LLY) - ophthalmology genetic medicine collaboration partner
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MGTX vs…
Frequently asked questions
What does MEIRAGTX HOLDINGS PLC (MGTX) do?
MeiraGTx is a clinical-stage genetic medicines company focused on developing therapies using localized delivery of genetic medicines to treat inherited and common diseases with high unmet need. The company has built comprehensive end-to-end manufacturing capabilities, including two GMP-licensed viral vector production facilities in London and Shannon, and a proprietary manufacturing platform optimized over 9+ years.
What sector is MEIRAGTX HOLDINGS PLC (MGTX) in?
MEIRAGTX HOLDINGS PLC (MGTX) is classified in the Health Care sector. Its industry is Gene therapy and genetic medicines. It trades on NASDAQ.
Who are MEIRAGTX HOLDINGS PLC's (MGTX) competitors?
Notable peers of MEIRAGTX HOLDINGS PLC (MGTX) include Spark Therapeutics, Audentes Therapeutics (now part of Astellas), Regenxbio, uniQure and Sangamo Therapeutics. This peer set is informational only — not financial advice.
Is MEIRAGTX HOLDINGS PLC (MGTX) overbought or oversold right now?
MEIRAGTX HOLDINGS PLC (MGTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 64, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MGTX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.